Parkside Financial Bank & Trust Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Parkside Financial Bank & Trust lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 16,979 shares of the company’s stock after selling 684 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Parkside Financial Bank & Trust’s holdings, making the stock its 22nd largest holding. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,774,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of JNJ. Morton Brown Family Wealth LLC lifted its position in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $39,000. Cardinal Capital Management Inc. lifted its position in Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust lifted its position in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock worth $40,960,735 in the last three months. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Morgan Stanley cut their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Raymond James cut their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, SVB Leerink cut their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Tuesday. The company has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The business has a 50 day simple moving average of $176.07 and a 200-day simple moving average of $171.13. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.